Abstract 1591P
Background
Gastric cancer (GC) is 5th most common cancer and 4th most common cause of cancer death worldwide. The rate of GC in patients < 40 years in different countries is ∼ 5%. The incidence and characteristics of GC in <40 patients were not studied in Georgian population. We analyzed clinicopathologic features of early onset GC in Georgia.
Methods
In this study we analyzed data from national cancer registry of Georgia 2015-2021. The data included number of cases, age, sex, anatomic location, stage, pathology and treatment types of GC. Aim of the study was to investigate clinicopathologic characteristics, treatment approaches and survival rates of GC in patients <40 compared to entire cohort. Survival was summarized by Kaplan-Meier method.
Results
A total of 1775 patients with GC were included in the study during 2015-2021. Out of 1775 patients 52 (2,9%) were < 40 years. Median age 34 (17-39). In <40 patients 50% were female, while in entire cohort 62% were male. No differences were seen in anatomic location, tumor grade, stage. Stage III (25 % in <40 patients vs 29% in entire cohort) and IV (40% vs 43%) were most common. Differences were seen in pathologic types - not otherwise classified adenocarcinoma 31% in <40 patients vs 25% in entire cohort (P value 0.3367), not otherwise classified carcinoma 26 % vs 2% (P value <0.0001), signet ring carcinoma 17% vs 6% respectively (P value 0.0004). In entire cohort rate of undifferentiated carcinoma was 30% and tubular adenocarcinoma 16%, which were not seen in <40 patients. 23% of <40 patients vs 30% entire cohort had surgery (P value 0.2294) and 42% vs 30% chemotherapy (P value 0.0714). Median overal survival (OS) for patients <40 was 20 months (95% CI 9,0-30,0) and 13 months for entire cohort (95% CI 12,0-15,0) (p value – 0,1488).
Conclusions
This study showed, that in Georgian <40 patients GC is equally distributed between both sexes, while in the entire cohort it is slighlty more common in males. Pathologic types as not otherwise classified carcinoma and signet ring carcinoma were seen most frequently in <40 patients. <40 patients were slightly more likely to receive chemotherapy and surgery. However, median OS was <2 years for patients <40. Further studies are required to understand causes of early onset GC in Georgian patients and to improve survival.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
T. Esakia.
Funding
Has not received any funding.
Disclosure
E. Smyth: Financial Interests, Personal, Invited Speaker: Amgen, Bristol Myers Squibb, Imedex, Merck, Novartis, Prova Education, Servier, TouchIME, Elsevier, PeerVoice, Cor2Ed, Daiichi Sankyo; Financial Interests, Personal, Other, TSC: Amgen; Financial Interests, Personal, Advisory Board: Astellas, AstraZeneca, Bristol Myers Squibb, Bristol Myers Squibb, My Personal Therapeutics, Novartis, Roche, Servier, Zymeworks, Viracta; Financial Interests, Personal, Other, IDMC: BeiGene, Zymeworks; Financial Interests, Personal, Other, IDMC chair: Everest Clinical Research; Financial Interests, Personal, Officer: EORTC GI Clinical Trials Group; Financial Interests, Institutional, Local PI: Daiichi Sankyo, Merus, Basilea, MSD, Mirati; Financial Interests, Institutional, Coordinating PI: Roche, AstraZeneca, Amgen; Financial Interests, Institutional, Research Grant: Bristol Myers Squibb; Non-Financial Interests, Leadership Role, Trustee: UK & Ireland Oesophagogastric Group (UKIOG). All other authors have declared no conflicts of interest.
Resources from the same session
1579P - Gender differences and worse metastatic survival outcomes in young adult patients with oesophagogastric cancer: 12-year data from a Czech comprehensive cancer center
Presenter: Tomás Sokop
Session: Poster session 22
1580P - Early onset oesophageal adenocarcinoma: A separate biological entity?
Presenter: Dharmesh Valand
Session: Poster session 22
1581P - Total neoadjuvant chemotherapy with FOLFIRINOX regimen in patients with resectable locally advanced gastric and gastroesophageal junction cancer
Presenter: Maria Sedova
Session: Poster session 22
1582P - Gastroesophageal adenocarcinoma in young adults: Retrospective analysis of clinical and molecular features
Presenter: Daniel Acosta Eyzaguirre
Session: Poster session 22
1583P - Intraperitoneal chemotherapy for peritoneal metastases of gastric origin: A systematic review and meta-analysis
Presenter: Niels Guchelaar
Session: Poster session 22
1585P - The impact of platinum-induced peripheral neuropathy (PN) in first-line treatment on PN and efficacy in second-line paclitaxel (PTX)-based chemotherapy for unresectable advanced gastric cancer (AGC): A prospective observational multicenter study - IVY study
Presenter: Yoshiyasu Kono
Session: Poster session 22
1587P - Analysis of survival outcomes according to start timing of adjuvant chemotherapy in patients with gastric cancer: A retrospective nationwide cohort study
Presenter: Tae-Hwan Kim
Session: Poster session 22
1588P - Analysis of risk factors of anastomotic leakage after minimally invasive esophagectomy with circular cervical anastomosis
Presenter: ming lu
Session: Poster session 22